Novo has led a $60m series C round for University of Dundee’s Exscientia that also attracted Evotec, Bristol-Myers Squibb, and GT Healthcare Capital.
Exscientia, a UK-based drug discovery technology spinout of University of Dundee, obtained $60m in a series C round today led by pharmaceutical firm Novo Holdings.
Drug discovery and development company Evotec, pharmaceutical firm Bristol-Myers Squibb and private equity firm GT Healthcare Capital, through unnamed limited partners, also took part in the round.
Incorporated in 2012, Exscientia exploits artificial intelligence technology for a drug discovery platform that taps into the outcomes of historic research to design compounds and rapidly…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
